|
CN112142745A
|
|
Casein kinase 1 inhibitor, pharmaceutical composition and application thereof
|
|
CN110483521A
|
|
A kind of reversible covalent bruton's tyrosine kinase inhibitor, pharmaceutical composition and its application
|
|
CN110483520A
|
|
The crystal form of bruton's tyrosine kinase inhibitor, preparation method and applications
|
|
CA3043376A1
|
|
Selective bruton's tyrosine kinase inhibitor and use thereof
|
|
CN109535200A
|
|
A kind of phosphoramidate prodrug, pharmaceutical composition and its application of nucleoside analog
|
|
WO2017101785A1
|
|
Compound, preparation method therefor, pharmaceutical composition thereof and use thereof
|
|
WO2016180334A1
|
|
Dual-site irreversible bruton's tyrosine kinase inhibitor, composition and application therefof
|
|
CN105777829A
|
|
Prodrug with nucleoside-analog-structure, and preparation method, medicinal composition and application thereof
|
|
CN105777759A
|
|
Bruton's tyrosine kinase inhibitor
|
|
CN105348345A
|
|
Prodrug containing tiopronin structure, preparation method of prodrug, pharmaceutical composition and application of pharmaceutical composition
|
|
CN104844609A
|
|
Double-site irreversible Brutons tyrosine kinase inhibitor
|
|
CN103315973A
|
|
Quetiapine osmotic pump controlled release preparation
|
|
CN102659638A
|
|
Synthetic method of leonurine
|
